Imukin

Interferon gamma, the active ingredient in Imukin, is a cytokine presented as a solution for injection for subcutaneous use. It treats chronic granulomatous disease and severe malignant osteopetrosis in appropriate patients.

GNH USA supplies Imukin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imukin (interferon gamma) modulates immune function and is indicated for specific rare immunodeficiency and bone disorders.

- Chronic granulomatous disease: improves host defense by enhancing macrophage killing of catalase‑positive organisms. - Severe malignant osteopetrosis: stimulates osteoclast differentiation to reduce bone density and improve hematopoiesis.

Common Side Effects: - Fever or chills - Injection‑site redness or swelling - Fatigue or malaise - Headache - Myalgia - Nausea

Serious or Rare Side Effects: - Autoimmune hepatitis - Severe allergic reactions including anaphylaxis - Neutropenia or other blood‑cell count abnormalities - Thrombocytopenia - Pulmonary alveolar proteinosis - Hemolytic anemia

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: check hepatic enzymes periodically. - Screen for autoimmune disease: avoid use in active autoimmune conditions. - Avoid in patients with known hypersensitivity to interferon gamma or formulation components. - Use with caution in active infections: weigh benefits against potential immune activation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Interferon gamma may interact with other agents that affect immune function or hemostasis.

Major Interactions (Avoid): - Live vaccines: concurrent use may reduce vaccine efficacy or increase adverse events. - High‑dose systemic steroids or other potent immunosuppressants: may blunt therapeutic effect. - Other cytokine therapies (e.g., interferon alpha): increased risk of overlapping toxicities.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR for potential potentiation of anticoagulation. - Methotrexate or other disease‑modifying agents: watch for additive bone‑marrow suppression. - Protease inhibitors or drugs affecting cytokine metabolism: observe for altered pharmacodynamics.